Coronavirus Update: Pfizer/BioNTech, Moderna Submit Omicron EUAs For Fall Season
Under FDA guidance, the companies submitted clinical data for BA.1-targeting bivalent vaccines together with BA.4/BA.5 preclinical data. Novavax got a nod for its COVID-19 vaccine in adolescents, but its own Omicron development efforts remain behind the two mRNA heavyweights.
You may also be interested in...
A senior executive at Moderna recounts how the company used a variety of data sources to identify potential safety signals for its Spikevax COVID-19 vaccine during a state of “hyper-pharmacovigilance.”
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.
Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.